We are live on ! Find out more
LPCN icon

Lipocine
LPCN

44 hedge funds and large institutions have $102M invested in Lipocine in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

869% more capital invested

Capital invested by funds: $10.5M → $102M (+$91.4M)

809% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $195K

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

13% more funds holding

Funds holding: 39 → 44 (+5)

0.09% more ownership

Funds ownership: 0.71% → 0.79% (+0.09%)

Holders
44
Holders Change
+5
Holders Change %
+12.82%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
13
Reduced
9
Closed
4
Calls
$1.77M
Puts
$195K
Net Calls
+$1.58M
Net Calls Change
+$611K

Top Buyers

1
EI
EAM Investors
California
+$810K
2
Marshall Wace
Marshall Wace
United Kingdom
+$693K
3
Two Sigma Investments
Two Sigma Investments
New York
+$317K
4
BCM
Bridgeway Capital Management
Texas
+$218K
5
AWA
Aaron Wealth Advisors
Illinois
+$145K

Top Sellers

1
GCP
GSA Capital Partners
United Kingdom
-$437K
2
Morgan Stanley
Morgan Stanley
New York
-$228K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$166K
4
BlackRock
BlackRock
New York
-$36.7K
5
HF
HRT Financial
New York
-$23K
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
26
XTX Topco
Cayman Islands
$54K +$48.4K +2,315 New
Jane Street
27
Jane Street
New York
$42K +$9.98K +477 +36%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$41K -$166K -7,946 -82%
MSAM
29
Moloney Securities Asset Management
Missouri
$31K – – –
TSS
30
Two Sigma Securities
New York
$26K +$23.3K +1,112 New
PMFA
31
Plante Moran Financial Advisors
Michigan
$23K – – –
CG
32
Cutler Group
California
$19K +$1.11K +53 +7%
Renaissance Technologies
33
Renaissance Technologies
New York
$19K +$17.3K +829 New
Creative Planning
34
Creative Planning
Kansas
$14K – – –
TRCT
35
Tower Research Capital (TRC)
New York
$12K +$7.37K +352 +233%
UBS Group
36
UBS Group
Switzerland
$10K +$4.14K +198 +84%
Wells Fargo
37
Wells Fargo
California
$5K -$711 -34 -14%
JP Morgan Chase
38
JP Morgan Chase
New York
$4K – – –
BFEC
39
Benjamin F. Edwards & Company
Missouri
$2K – – –
Osaic Holdings
40
Osaic Holdings
Arizona
$2K – – –
Bank of America
41
Bank of America
North Carolina
$1K -$209 -10 -14%
Citigroup
42
Citigroup
New York
$1K +$607 +29 New
GCP
43
GSA Capital Partners
United Kingdom
– -$437K -25,908 Closed
HF
44
HRT Financial
New York
– -$23K -1,422 Closed
PPW
45
Pinnacle Private Wealth
Massachusetts
– -$15K -897 Closed
ECM
46
ExodusPoint Capital Management
New York
– -$12K -689 Closed
Fidelity Investments
47
Fidelity Investments
Massachusetts
– -$63 -3 -27%
Walleye Trading
48
Walleye Trading
New York
– +$126 +6 New
1
2

LPCN Hedge Fund Activity: Q1 2022 in Review

44 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2022, worth a combined $102M — up 869% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new LPCN positions and 4 closed out — a net gain of 5 holders — while 13 added to existing stakes and 9 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $810K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $437K sold.

  • 44 institutional investors held Lipocine (LPCN) as of Q1 2022, up from 39 in Q4 2021.
  • Funds reported $102M of Lipocine stock for Q1 2022, up 869% quarter-over-quarter.
  • 9 funds opened new Lipocine positions in Q1 2022 and 4 closed out, a net change of +5 holders.
  • The largest Lipocine buyer in Q1 2022 was EAM Investors, an estimated $810K added.
  • The largest Lipocine seller in Q1 2022 was GSA Capital Partners, an estimated $437K sold.

Based on aggregated 13F filings for Q1 2022.